Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan

Table 3 Adverse effects and liver function abnormality tests of the 84 virologically suppressed HIV-infected patients entered in this study

a Comparison of adverse effects between NVP-XR and NVP-IR
	All N = 84	NVP-XR N = 35			NVP-IR N = 49				P
Skin rash, n (%)	1 (1.2)	1 (2.9)			0 (0.0)				0.42
Gastrointestinal disorders, n (%)	2 (2.4)	1 (2.9)			1 (2.0)				1.0
Tablet remnants in stools, n (%)	1 (2.4)	1 (2.9)			0 (0.0)				0.42
b Comparison of liver function abnormalities between NVP-XR and NVP-IR
	NVP-XR 400 mg qd (N = 35)				NVP-IR 200 mg bid (N = 49)				P
AST elevation, n (%)	6 (17.1)				12 (24.5)				0.42
	Grade I	Grade II	Grade III	Grade IV	Grade I	Grade II	Grade III	Grade IV
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
	5 (14.3)	0 (0)	0 (0)	1 (2.9)	10 (22.4)	1 (2.0)	1 (2.0)	0 (0)	0.28
ALT elevation, n (%)	9 (25.7)				16 (32.7)				0.49
	Grade I	Grade II	Grade III	Grade IV	Grade I	Grade II	Grade III	Grade IV
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
	8 (22.9)	0 (0)	0 (0)	1 (2.9)	13 (28.6)	2 (4.1)	1 (2.0)	0 (0)
Bilirubin, n (%)	1 (2.9)				0 (0)				0.42
	Grade I	Grade II	Grade III	Grade IV	Grade I	Grade II	Grade III	Grade IV
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
	1 (2.9)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

AST aspartate aminotransferase, ALT alanine aminotransferase
(a) Comparison of adverse effects between NVP-XR (n = 35) and NVP-IR (n = 49). (b) Comparison of liver function abnormalities between NVP-XR (n = 35) and NVP-IR (n = 49)

ISSN: 1471-2334